This Project Grant award of $600,124 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research by IHC Health Services Inc. (doing business as Intermountain Healthcare) to enhance the clinical identification of individuals at risk of moderate to severe mitral valve prolapse (MVP) and associated health events.
The key objectives are to: 1) Describe the history of MVP, related cardiac morbidities, and other contributing conditions using Intermountain Healthcare's extensive electronic health record data; 2) Evaluate heritable risk factors for MVP endpoints by leveraging population genealogy and large-scale genetic testing; and 3) Develop novel clinical decision tools using electronic health record data to stratify risk of severe health outcomes for people with MVP. This research aims to resolve disconnects in MVP risk assessment and treatment by providing standardized, clinically-implementable risk assessment tools to achieve the healthiest MVP outcomes possible.
Generated 3/4/25, 2:59 AM